Buloxibutid

Buloxibutid (AT2 receptor agonist C21) is a agentlike selective angiotensin II AT2 receptor agonist with Ki values of 0.4 nM and >10 μM for the AT2 receptor and AT1 receptor, respectively[1].

Product Specifications

CAS Number

[477775-14-7]

Product Name Alternative

AT2 receptor agonist C21

UNSPSC

12352005

Hazard Statement

H302, H312, H315, H319

Target

Angiotensin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/buloxibutid.html

Purity

99.02

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(OCCCC)NS(=O)(C1=C(C2=CC=C(CN3C=CN=C3)C=C2)C=C(CC(C)C)S1)=O

Molecular Formula

C23H29N3O4S2

Molecular Weight

475.62

Precautions

H302, H312, H315, H319

References & Citations

[1]Wan Y, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004 Nov 18;47 (24) :5995-6008.|[2]Schwengel K, Namsolleck P, Lucht K, et al. Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice. J Mol Med (Berl) . 2016;94 (8) :957-966. |[3]Fatima N, Patel S, Hussain T. Angiotensin AT2 Receptor is Anti-inflammatory and Reno-Protective in Lipopolysaccharide Mice Model: Role of IL-10. Front Pharmacol. 2021;12:600163.